Skip to main content
. Author manuscript; available in PMC: 2019 Oct 27.
Published in final edited form as: Ann Surg. 2018 Feb;267(2):364–369. doi: 10.1097/SLA.0000000000002088

TABLE 1.

Summary of Studies Evaluating HuR as a Predictive Marker for Pancreatic Ductal Adenocarcinoma in the Adjuvant Setting

First Author Year Patient Population No. Samples Therapy Findings
Costantino et al13 2009 TJUH 40 GEM ±Xeloda ± XRT High cHuR: negative prognostic marker (OS HR 7.34, CI 2.05–26.22, p = 0.0022)
Richards et al12 2010 TJUH 53 GEM (n = 24) High cHuR: negative prognostic marker (OS HR 2.84, CI 1.04–7.74, P = 0.04)
No adjuvant therapy or follow-up (n = 21) High cHuR: higher AJCC T stage (P = 0.005)
McAllister et al14 2014 RTOG9704 165 GEM + XRT (n = 76) cHuR: no prognostic or predictive value
5-FU + XRT (n = 89)
This study 2016 ESPAC-3 379 GEM (n = 193) 5-FU (n = 186) High cHuR: positive predictive marker for 5-FU (DFS HR 0.51, CI 0.3–0.85, P = 0.01)
5-FU (n = 186)